Aberrant DNA methylation plays a pivotal role in tumor development and progression. DNA
hypomethylating agents (HMA) constitute a class of drugs which are able to reverse DNA …

Our understanding of the genetics of acute myeloid leukemia (AML) development from
myelodysplastic syndrome (MDS) has advanced significantly as a result of next-generation …

Successful treatment of acute myeloid leukemia (AML) with chimeric antigen receptor (CAR)
T cells is hampered by toxicity on normal hematopoietic progenitor cells and low CAR T cell …

Several mechanisms of action have been proposed for DNA methyltransferase and histone
deacetylase inhibitors (DNMTi and HDACi), primarily based on candidate-gene approaches …

Abstract Treatment of relapsed or refractory acute myeloid leukemia (AML) has presented
challenges for hematologists for decades. Despite numerous clinical studies, outcomes are …

The success of hematopoietic stem cell transplantation (HSCT) lies with the ability of the
engrafting immune system to remove residual leukemia cells via a graft-versus-leukemia …

To expand the current knowledge about azacitidine (Aza) and donor lymphocyte infusions
(DLI) as salvage therapy for relapse after allogeneic hematopoietic stem cell transplantation …

Disease relapse is the major causes of treatment failure after allogeneic stem cell
transplantation (SCT) in patients with acute myeloid leukemia (AML). As well as …

Relapse of the original disease is a major cause of death after allogeneic hematopoietic cell
transplantation for acute leukemias. There is growing evidence that relapses may be …

Acute myeloid leukemia (AML) is a phenotypically and prognostically heterogeneous
hematopoietic stem cell disease that may be cured in eligible patients with intensive …